drugset
drugset / Trial / NCT02693769

A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils

NCT02693769 ↗

Phase 2/3 Terminated 2 enrolled Mundipharma Research Limited
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to investigate whether fluticasone/formoterol Breath actuated inhaler is effective and well tolerated in the treatment of subjects with fixed airflow obstruction and elevated eosinophils.

Timeline

Start
2016-07
Primary completion
2016-10
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Other / unclassified 125 ug Inhaled
Subject Formoterol Other / unclassified 5 ug Inhaled
Subject Glycopyrronium Unknown 43 ug Inhaled
Subject Indacaterol Other / unclassified 85 ug Inhaled

Indications

asthma